What is the official website of PHOENIX Pharma Bulgaria ?

The official website of PHOENIX Pharma Bulgaria is http://www.phoenixpharma.bg.

What is PHOENIX Pharma Bulgaria's cybersecurity risk score?

PHOENIX Pharma Bulgaria has an AI-generated cybersecurity risk score of 754 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has PHOENIX Pharma Bulgaria experienced?

According to Rankiteo, PHOENIX Pharma Bulgaria currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has PHOENIX Pharma Bulgaria been affected by any supply chain cyber incidents ?

According to Rankiteo, PHOENIX Pharma Bulgaria has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does PHOENIX Pharma Bulgaria have SOC 2 Type 1 certification ?

According to Rankiteo, PHOENIX Pharma Bulgaria is not certified under SOC 2 Type 1.

Does PHOENIX Pharma Bulgaria have SOC 2 Type 2 certification ?

According to Rankiteo, PHOENIX Pharma Bulgaria does not hold a SOC 2 Type 2 certification.

Does PHOENIX Pharma Bulgaria comply with GDPR ?

According to Rankiteo, PHOENIX Pharma Bulgaria is not listed as GDPR compliant.

Does PHOENIX Pharma Bulgaria have PCI DSS certification ?

According to Rankiteo, PHOENIX Pharma Bulgaria does not currently maintain PCI DSS compliance.

Does PHOENIX Pharma Bulgaria comply with HIPAA ?

According to Rankiteo, PHOENIX Pharma Bulgaria is not compliant with HIPAA regulations.

Does PHOENIX Pharma Bulgaria have ISO 27001 certification ?

According to Rankiteo,PHOENIX Pharma Bulgaria is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does PHOENIX Pharma Bulgaria operate in ?

PHOENIX Pharma Bulgaria operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does PHOENIX Pharma Bulgaria have ?

PHOENIX Pharma Bulgaria employs approximately 339 people worldwide.

Does PHOENIX Pharma Bulgaria own any subsidiaries ?

PHOENIX Pharma Bulgaria presently has no subsidiaries across any sectors.

How many LinkedIn followers does PHOENIX Pharma Bulgaria have ?

PHOENIX Pharma Bulgaria's official LinkedIn profile has approximately 12,636 followers.

What is the NAICS classification code for PHOENIX Pharma Bulgaria ?

PHOENIX Pharma Bulgaria is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does PHOENIX Pharma Bulgaria have a Crunchbase profile ?

No, PHOENIX Pharma Bulgaria does not have a profile on Crunchbase.

Does PHOENIX Pharma Bulgaria have a LinkedIn profile ?

Yes, PHOENIX Pharma Bulgaria maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/phoenix-pharma-bulgaria.

How many cybersecurity incidents has PHOENIX Pharma Bulgaria experienced ?

As of August 27, 2026, Rankiteo reports that PHOENIX Pharma Bulgaria has not experienced any cybersecurity incidents.

How many peer or competitor companies does PHOENIX Pharma Bulgaria have ?

PHOENIX Pharma Bulgaria has an estimated 5,737 peer or competitor companies worldwide.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

PPB

Boost Score +25 with badge (5 left)

754

/1000

Fair

779

/1000

Fair

PHOENIX Pharma Bulgaria Vendor Cyber Rating & Cyber Score

phoenixpharma.bg

Add Your Compliance Badge

PHOENIX Pharma EOOD is leading pharmaceutical wholesaler in Bulgaria. As part of the PHOENIX Group, we offer a wide range of services, providing daily seamless deliveries of medicines and other healthcare products. We deliver about 10 million packages every day on a global level, wherever they are needed. Reliable, fast national coverage in 27 European countries. PHOENIX Pharma EOOD provides 100% national coverage in Bulgaria, thanks to its long-term professional experience and its warehouse facilities located in 5 key points of the country. Our exclusively designed and well-developed distribution network allows the company to build excellent business relations with almost all pharmacies and hospitals in Bulgaria. To date, we have been

PPB A.I CyberSecurity Scoring

Scoring History

PPB

PHOENIX Pharma Bulgaria CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

No data available

Loading…

A.I.

PPB Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for PPB

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for PHOENIX Pharma Bulgaria in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for PHOENIX Pharma Bulgaria in 2026.

Incident Types PPB vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for PHOENIX Pharma Bulgaria in 2026.

Incident History - PPB (X = Date, Y = Severity)

Loading…

SUBSIDIARY

PHOENIX Pharma Bulgaria Subsidiaries

PPB

Pharmaceutical Manufacturing

Website: http://www.phoenixpharma.bg

Company Size: 501-1,000 employees

PHOENIX group - Integrated Healthcare ProviderWholesale

BENU FarmaciaPharmaceutical Manufacturing

Gruppo ComifarTransportation, Logistics, Supply Chain and Storage

NomecoTransportation, Logistics, Supply Chain and Storage

Help Net FarmaPharmaceutical Manufacturing

Apotek 1Pharmaceutical Manufacturing

FarmeximWholesale Drugs and Sundries

PHX IrelandPharmaceutical Manufacturing

OCP PortugalWholesale

PHOENIX Pharmahandel GmbH & Co KGWholesale

PHOENIX FarmacijaPharmaceutical Manufacturing

EL PHARMA – PHOENIX group Representation ServicesHealth and Human Services

PHOENIX Medical Supplies LtdPharmaceutical Manufacturing

PHOENIX Pharma Switzerland AGHealth and Human Services

PHOENIX BelgiumHospitals and Health Care

BENU BelgiumPharmaceutical Manufacturing

Tamro FinlandWholesale

Tamro BalticsPharmaceutical Manufacturing

Tamro SwedenPharmaceutical Manufacturing

SmilaHospitals and Health Care

Pharmacies BENU SAPharmaceutical Manufacturing

Kemofarmacija d.d.Wholesale

SOFIADISWholesale

PHOENIX Zdravotnícke zásobovanie, a.s.Wholesale

BENU SlovenskoPharmaceutical Manufacturing

PHOENIX Pharma ItaliaWholesale

Loading…

PHOENIX Pharma Bulgaria Similar Companies

Teva Pharmaceuticals

tevapharm.com

Teva Pharmaceuticals is a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how we make it happen, visit www.tevapharm.com. Our community guidelines may be found here: https://www.tevapharm.com/news-and-media/teva-social-media-guidelines/ Please note that adverse effects for any of our products should be reported at: https://www.tevapharm.com/teva-medical-information/report-a-side-effect-form/ Product-specific questions should be directed to Teva or Teva Group subsidiaries in your country. Contact details and Teva's Pharmacovigilance Privacy Policy may be found here: http://www.tevapharm.com/contact_us/

Servier

servier.com

Founded to serve health 70 years ago, Servier is a global pharmaceutical group governed by a non-profit Foundation that aspires to make a meaningful social impact for patients and for a sustainable world. The Group’s unique governance model preserves its independence and means it can fully serve its vocation of being committed to therapeutic progress to serve patient needs while adopting a long-term vision. Its employees are fully committed to this shared vocation, which serves as a source of inspiration every day. A world leader in cardiometabolism and venous diseases, Servier has made a major shift into oncology, which represents a new pillar of strategic growth. The Group devotes close to 70% of its R&D budget to this field, with the ambition of becoming a focused and innovative player in the development of treatments targeting rare cancers. Neurology will constitute a future growth driver. Servier is focusing on a limited number of diseases in this area where accurate patient profiling makes it possible to offer a targeted therapeutic response through precision medicine. To promote widespread access to quality care at a lower cost, the Group also offers a range of quality generic drugs covering most pathologies, leveraging well-known brands in France, and Eastern Europe. In all these areas, the Group takes patient considerations into account at every stage of the medicine life cycle. Headquartered in France, Servier relies on committed teams and strong geographical footprint; its medicines are available in close to 140 countries. In 2023/2024, the Group achieved sales revenue of €5.9 billion and EBITDA of €1.3 billion in 2024 (22.2%). Today, the Group employs over 22,000 people worldwide. -- To report a suspected adverse event with a Servier drug, please visit servier.com

Catalent

catalent.com

Championing the missions that matter™. Catalent, Inc. is a leading global contract development and manufacturing organization (CDMO) and trusted partner to pharma, biotech, and consumer health companies worldwide. We put patients first in everything we do, helping people live better and healthier lives through every product we help develop, manufacture and deliver. With over 1,000 active development programs at any given time, we launch over 100 new products and line extensions annually. Catalent has supported half of all FDA approvals over the past decade, and our teams working at over 40 global sites help us produce over 60 billion doses every year. Our strength lies in our people: teams across our more than 40 sites and thousands of passionate scientists and technicians who bring expertise in development sciences, delivery technologies, and multi-modality manufacturing. What unites us is our commitment to championing our partners’ missions as our own, anticipating customer needs, solving complex challenges and ultimately making a difference in the lives of patients across the globe. At Catalent, you will be able to directly have an impact, solving problems and ensuring excellence for our customers. Our focus on delivering meaningful outcomes alongside our customers means your work directly impacts millions of people around the world. Join us in championing the missions that matter. Catalent is headquartered in Tampa, Florida, with over 40 global sites. Visit www.catalent.com to learn more.

Parexel

parexel.com

Parexel is a leading global clinical research organization (CRO) providing insights-driven Clinical and Consulting solutions to the world’s life sciences industry. Leveraging deep local knowledge and a global breadth of clinical, regulatory and therapeutic expertise, our 24,000+ professionals worldwide work in partnership with biopharmaceutical leaders, emerging innovators and sites to design and deliver clinical trials with patients in mind — broadening access and making clinical research a care option for anyone, anywhere. Our proven track record spans 40+ years and drives us forward, advancing clinical research in healthcare’s most complex areas while harnessing innovation to drive efficiencies across every phase of the clinical development process. Our insights-driven approach, proven delivery and trusted execution are accelerating the delivery of life-changing treatments to patients — With Heart.™ We continue to earn recognition industrywide, including the 2025 Scrip Award for “Best Contract Research Organization – Full-Service Provider,” 2024 Fierce Biotech CRO Award for "Innovative Approaches to Patient-Centric Research" and the 2024 and 2023 Society for Clinical Research Sites (SCRS) Eagle Award. Community Guidelines Because Parexel’s social media channels are open to the general public and employees, we are not responsible for views expressed other than our own. However, we do not tolerate posts that are: • Abusive, harassing or threatening to others. • Defamatory, offensive, obscene, vulgar or depicting violence. • Hateful targeting by race/ethnicity, age, color, creed, religion, gender, sexual preference or orientation, nationality or political beliefs. • Sexually explicit or pornographic. • Fraudulent, deceptive, libelous, misleading or unlawful. • Referencing criminal or illegal activity. • Spamming. We reserve the right to remove comments that do not adhere to our guidelines and report users who violate the rules of our page.

AUROBINDO PHARMA LTD

aurobindo.com

Aurobindo Pharma Limited (NSE: AUROPHARMA, BSE: 524804, Reuters: ARBN.NS, Bloomberg: ARBP IN) is an integrated global pharmaceutical company headquartered in Hyderabad, India. The Company develops, manufactures, and markets a wide range of generic pharmaceuticals, branded specialty drugs, and active pharmaceutical ingredients (APIs) across more than 150 countries. It is ranked among the top 10 generic companies in eight European nations and holds the distinction of being the largest generic pharmaceutical company in the United States. With over 30 state-of-the-art manufacturing and packaging facilities approved by leading global regulatory authorities including USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC, and Brazil ANVISA, Aurobindo Pharma ensures the highest standards of quality. Its robust portfolio spans eight major therapeutic areas: Central Nervous System (CNS), Antiretroviral (ARV), Cardiovascular (CVS), Antibiotics, Gastroenterology, Anti-diabetics, Oncology, and Dermatology, supported by a strong R&D infrastructure that drives innovation, affordability, and accessibility.

Hikma Pharmaceuticals

cb hikma.com

For almost 50 years, we’ve been creating high-quality medicines and making them accessible to the people who need them. We are a trusted, reliable partner and dependable source of over 800* high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe. We have 29 manufacturing plants, 3 R&D hubs and c9,500 employees worldwide. *As of December 2025 Subscribe to our channel on YouTube https://youtube.com/@hikmapharmaceuticals5668 For all product information and enquiries, please contact us at [email protected]

Novo Nordisk

cb novonordisk.com

We’re not your typical healthcare company. In a modern world of quick fixes, we focus on solutions to defeat serious chronic disease and create long-term health. We seek out new ideas and put people first as we push the boundaries of science, make healthcare more accessible, and work to treat, prevent, and even cure diseases that affect millions of lives. Founded in Denmark in 1923, today we employ more than 68,800 people in 80 offices around the world – all united by our bold purpose to drive change to defeat serious chronic diseases. Want to learn more? Visit www.novonordisk.com. This page isn’t intended for discussions about products. As such, postings or comments that contain product discussions may be removed. This page is for discussions about Novo Nordisk and its subsidiaries and the initiatives and projects we are involved in. While we welcome everyone to make comments, we reserve the right to block and remove those that are off-topic, abusive or intended to spam. Any questions specific to products should be made to your healthcare professional. If you wish to file an adverse drug reaction please contact Novo Nordisk’s office in the country you live in: https://www.novonordisk.com/contact-us/find-local-information.html For other customer complaints, please contact us here: https://www.novonordisk.com/contact-us.html Please keep in mind that Novo Nordisk A/S and its subsidiaries work within a highly regulated industry. Therefore, comments that pertain to legal matters or regulatory issues may be removed. Comments contained on this site come from members of the public, and do not necessarily reflect the views of Novo Nordisk A/S. Novo Nordisk A/S does not endorse or approve any content added by other LinkedIn users. Learn more about our privacy disclaimer and community guidelines here: https://www.novonordisk.com/data-privacy-and-user-rights/social-media-privacy-disclaimer.html

MENARINI Group

menarini.com

The Menarini Group is a leading international pharmaceutical and diagnostics company, present in 140 countries worldwide, with a turnover of 4,37 Billion euro and more than 17,000 employees. With 9 centers for Research & Development, Menarini’s products are present in the most important therapeutic areas, including cardiology, oncology, gastroenterology, pneumology, infectious diseases, diabetes, and anti-inflammatory/analgesics. The Group’s pharmaceutical production is carried out in its 18 manufacturing plants, which produce over 609 million packets of product a year and distribute them to five continents. Menarini’s pharmaceutical production, in line with the highest quality standards, provides an ongoing contribution to the health of patients all over the world. For further information, please visit www.menarini.com For reading our Netiquette, please visit https://www.menarini.com/en-us/data-privacy/netiquette-of-menarini-group For reading our Privacy Notice for social networks users, please visit https://www.menarini.com/en-us/data-privacy/privacy-notice-for-social-network-users-of-menarini-group

Alembic Pharmaceuticals Limited

alembic-india.com

Established in 1907, Alembic Pharmaceuticals Limited is a leading pharmaceutical company in India. The Company is vertically integrated with the ability to develop, manufacture and market pharmaceutical products, pharmaceutical substances and Intermediates. Alembic is the market leader in the Macrolides segment of anti-infective drugs in India. Alembic's manufacturing facilities are located in Vadodara and Baddi in Himachal Pradesh. The plant at Vadodara has the largest fermentation capacity in India. The Panelav facility houses the API and formulation manufacturing (both US FDA approved) plants. The plant at Baddi, Himachal Pradesh manufactures formulations for the domestic and non-regulated export market. The company has a state of the art Research Centre at Vadodara.

Loading…

NEWS

PHOENIX Pharma Bulgaria CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-81203

SUMMARY

A vulnerability has been found in SourceCodester Simple Online Food Ordering System 1.0. This affects an unknown function of the file /admin/ajax.php?action=login2. The manipulation of the argument email leads to sql injection. It is possible to initiate the attack remotely. The exploit has been disclosed to the public and may be used.

Published

Date2026-08-26

Updated

Date2026-08-26

RISK INFORMATION (Score: 7.3)

cvss2

Base Score: 7.5

Complexity: LOW

AV:N/AC:L/Au:N/C:P/I:P/A:P

cvss3

Base Score: 7.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:L/I:L/A:L

cvss4

Base Score: 5.5

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.4

Exploitability

3.9

REFERENCES

CVE-2026-80158

SUMMARY

A flaw was found in the ipa_getkeytab module of the community.general Ansible collection. The module's bind_pw parameter, used to supply the LDAP simple-bind password when retrieving a Kerberos keytab, is not declared with no_log, unlike the sibling password parameter in the same module. As a consequence, the supplied IPA/LDAP bind password is recorded in cleartext in the managed host's system journal/syslog (the module's "Invoked with" record), is included in the module's return values and verbose (-v) output, and is displayed in Automation Controller / AWX job output. The password is additionally passed on the command line to the ipa-getkeytab helper (as --bindpw <value>), exposing it in the process list to local users while the command runs. An attacker able to read these logs, job output, or the process table can obtain the directory bind credential, potentially compromising the accounts and objects that credential can access.

Published

Date2026-08-26

Updated

Date2026-08-26

RISK INFORMATION (Score: 5.5)

cvss3

Base Score: 5.5

Complexity: LOW

CVSS:3.1/AV:L/AC:L/PR:L/UI:N/S:U/C:H/I:N/A:N

Impact Score

3.6

Exploitability

1.8

REFERENCES

CVE-2026-75340

SUMMARY

The device metadata import interface /device/instance/{productId}/property-metadata/import of jetlinks community 2.11 is vulnerable to Server-side request forgery (SSRF).

Published

Date2026-08-26

Updated

Date2026-08-26

RISK INFORMATION (Score: )

Impact Score

Exploitability

REFERENCES

https://github.com/fangtang7/CVE/blob/main/jetlinks-community/ssrf.md

CVE-2026-75338

SUMMARY

disconf (Distributed Configuration Management Platform) 2.6.36 is vulnerable to Incorrect Access Control. The config-fetching APIs /api/config/item, /api/config/file, /api/config/list and /api/config/simple/list are exposed without authentication. The LoginInterceptor explicitly whitelists these four paths, so any anonymous attacker can read every configuration item and configuration file managed by the config center.

Published

Date2026-08-26

Updated

Date2026-08-26

RISK INFORMATION (Score: )

Impact Score

Exploitability

REFERENCES

https://github.com/fangtang7/CVE/blob/main/disconf/Unauthenticated.md

CVE-2026-75336

SUMMARY

Funiture 1.0.0 is vulnerable to SQL Injection in the backend tool interfaces /sys/tool/select.json and /sys/tool/update.json.

Published

Date2026-08-26

Updated

Date2026-08-26

RISK INFORMATION (Score: )

Impact Score

Exploitability

REFERENCES

https://github.com/fangtang7/CVE/blob/main/funiture/SQL%20Injection.md

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…